ASCO 2022 Conference Coverage
Health-Related Quality of Life in R/R MM Treated With Teclistamab, a B-Cell Maturation Antigen x CD3-Bispecific Antibody: PROs in MajesTEC-1
This video was recorded prior to the FDA approval of teclistamab-cqyv (TECVAYLI) for adult patients ...
read more ↘
read more ↘
Login to view comments.
Click here to Login
